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ABSTRACT 
 
MING-YI CHOU: Modulation of Murine Bone Marrow-derived CFU-F and CFU-OB by 
in vivo Bisphosphonate and Fluoride Treatment 
(Under the direction of Eric T. Everett, Ph.D.) 
 
 
Bisphosphonates (BPN) are potent inhibitors of bone resorption with suggested 
dose dependent effects on osteoblasts.  Fluoride (F) is an anabolic agent capable of 
increasing bone mass and, depending upon genetic background, stimulates 
osteoclastogenesis.  This study aimed to investigate BPN and F’s in vivo effects on 
bone marrow derived osteoprogenitor cells. 
Mice from the C3H/HeJ (C3H), C57BL/6J (B6), FVB/NJ (FVB) and BALB/cByJ 
(BALB-c) strains were treated for 3-weeks with 0, 3, 30, or 150 mcg/kg/week 
alendronate (ALN) administered s.c. alone or in combination with 50ppm fluoride (F).  
Bone marrow cells were harvested and subjected to in vitro CFU-F and CFU-OB 
assays. 
Results showed strain dependent baseline differences in CFU-F, CFU-OB/ALP+, 
and CFU-OB/total. ALN and F treatments resulted in strain specific responses for 
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CFU-F, CFU-OB/ALP+, and CFU-OB/total.  No dose responses to ALN were 
observed.  Genetic factors appear to play a role in ALN’s effects on CFU-F and 
CFU-OB/total, but not on CFU-OB/ALP+. 
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CHAPTER 1 
INTRODUCTION 
Bisphosphonates 
Bisphosphonates (BPNs) are a major class of compounds used for the treatment 
of bone diseases such as Paget’s disease of bone, multiple myeloma, bone 
metastases, osteoporosis (adults), and pediatric bone diseases (i.e. osteogenesis 
imperfecta).    All BPNs contain two phosphonate groups attached to a single 
carbon atom, forming a “P-C-P” structure.  The presence of the two phosphate 
groups is essential for targeting the compound to bone and for its molecular 
mechanism of action. They are stable analogues of naturally occurring inorganic 
pyrophosphate, resistant to enzymatic and chemical breakdown.  BPNs have high 
affinity for hydroxyapatite (HAP) crystals.  BPNs have multiple direct effects on HAP 
and can inhibit calcification, crystal growth, and crystal dissolution.  BPNs have 
highly selective localization and retention in bone.  They preferentially 
compartmentalize to bone and can achieve high local levels with prolonged 
deposition.(1-3)   
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Bisphosphonates have two side groups: R1 and R2. (Figure 1)  When R1 is 
an –OH group, binding to calcium, and therefore bone, is enhanced.  R2 group 
determines the compound’s anti-resorptive potency biochemically, including effects 
on binding to HAP.(3) 
 
Figure 1. The generic structure of bisphosphonate and its functional domains, R1 and 
R2.  
 
 Bisphosphonates can be classified into two groups based on the molecular 
modes of action.  All BPNs bind to bone mineral.  The simpler non-nitrogen 
containing BPNs, such as etidronate and clodronate, (Figure 2) can be metabolically 
incorporated into non-hydrolyzable analogues of adenosine triphosphate (ATP) that 
may inhibit ATP-dependent intracellular enzymes.  The earliest clinical applications 
of BPNs included use of etidronate as an inhibitor of calcification in fibrodysphasia 
ossificans progressive and in patients who had undergone total hip replacement 
surgery to prevent subsequent heterotropic ossification and improve mobility.(3)  
Simple BPNs are also extremely useful as agents for bone imaging, in detecting bone 
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metastases and bone lesions, due to their high affinity to bone mineral.(4)   
 
Figure 2. Etidronate—a simple non-nitrogen containing bisphosphonate 
 
The most impressive clinical application of bisphosphonates involves the use of 
the more potent nitrogen-containing BPNs, as inhibitors of bone resorption, especially 
for diseases in which no effective treatment existed previously.  BPNs can inhibit 
bone resorption indirectly through impairment of osteoclast function.  The 
nitrogen-containing BPNs, such as alendronate, risedronate, ibandronate, and 
zoledronic acid, (Figure 3) are not metabolized, but can inhibit a key enzyme, farnesyl 
pyrophosphate synthase (FPPS) within the mevalonate pathway.  FPPS is crucial 
for the biosynthesis of isoprenoid lipids involved in the post-translational modification, 
prenylation, of small GTP-binding proteins, which are also GTPases, such as Ras, 
cdc42, Rab, Rho, and Rac.  Small GTPases are important signaling proteins that 
regulate a variety of cell processes including cell morphology, cytoskeletal 
arrangement, membrane ruffling, trafficking of vesicles, and apoptosis, all of which 
are essential for osteoclast formation, function and survival.  The inhibition of protein 
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prenylation and the disruption of the function of these key regulatory proteins result in 
the loss of osteoclastic activity.(1-3) 
 
Figure 3. Alendronate—a nitrogen-containing bisphosphonate 
 
Bisphosphonates are potent inhibitors of bone resorption.  Alendronate, a BPN 
characterized by a free amino group in its side chain, is approved as therapy and 
widely used for prevention of postmenopausal osteoporosis.(1-3,5)  BPNs disrupt 
osteoclast cellular metabolism and induce apoptosis in osteoclasts.(6-9)  BPNs 
inhibit osteoclast differentiation(10) and prevent fusion of osteoclast 
precursors.(11,12)  BPNs also indirectly suppress bone resorption by stimulating the 
osteoblasts to produce an osteoclast-inhibitory factor.(13-15)  The effects BPNs 
have on osteoclasts are much better understood than their effects on osteoblasts. 
Recent studies demonstrate a role of bisphosphonates on osteoblast function.  
BPNs exhibit biphasic effects on osteoblastic cell precursors in vitro—stimulatory at 
low doses and inhibitory at higher doses.(16,17)  At a lower dose/exposure, ALN 
inhibits osteoblast apoptosis.(18,19)  Several investigators also noted that low 
  5
dose/exposure of BPNs stimulates osteoblast proliferation and differentiation in 
vitro.(17,20,21)  On the other hand, at a higher dose/exposure, BPNs have been 
shown to exhibit no stimulatory effect on osteoblasts(22,23) and suppress bone 
formation independently of bone resorption.(24)  Effects of bisphosphonates, such 
as ALN, have been observed to be dose dependent and animal model dependent.(25)  
However, no study has investigated the dose-dependent modulation of formation of 
early and late osteoblastic cell precursors by in vivo ALN treatments with genetic 
background as a factor.   
Bisphosphonates also have actions on angiogenesis.  Clodronate, risedronate, 
ibandronate, pamidronate and zoledronic acid have anti-angiogenic actions.(26-28)  
Bisphosphonates can inhibit in vitro proliferation, chemotaxis, circulation, and 
capillary formation of bone marrow endothelial cells via VEGF and VEFG 
receptors.(29-31)  Furthermore, bisphosphonates can lead to transient reduction in 
circulating levels of VEFG, bFGF, and Mmp2 following zolendronate infusion.(32) 
 
Fluoride 
Fluoride is an important micronutrient which, similar to bisphosphonates, 
preferentially compartmentalizes to bone and accumulates with deposition.(33,34)  
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Fluoride is known for its anabolic effects on bone and its use as a therapeutic agent 
for postmenopausal osteoporosis has been investigated with mixed results.(35,36)  
Fluoride can affect osteoblasts anabolically in vivo(37) and in vitro(33) through 
undetermined mechanism and result in increase in osteoblast proliferation and 
activities, and increased bone formation.(38)  It has been demonstrated using inbred 
mouse strains that genetic factors play a role in the effects of fluoride both in dental 
fluorosis(39) and in variation in bone properties in response to fluoride exposure(40).  
Past bone histomorphometric studies have suggested that it is the increase in bone 
formation, and not the reduction in bone resorption, that is responsible for the 
increase in bone mass by fluoride treatment.(41,42)  Nevertheless, Yan et al.(43) 
used B6 and C3H inbred strains of mice to show that generic background influences 
fluoride’s effect on osteoclastogenesis.  Since both fluoride and bisphosphonate 
target the same physiological compartment, it is possible that bisphosphonate will 
modulate fluoride’s effects on the bone-formation process with genetic background 
as a factor. 
 
Bone marrow derived MSCs and osteogenic potential 
In 1970s, Friedenstein et al. first showed that bone marrow stroma contains cells, 
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referred to as marrow stromal cells or mesenchymal stem cells (MSC), with the 
capacity to form bone when transplanted in vivo.(44,45)  These precursors of 
non-hematopoietec cells have also been referred to as plastic-adherent cells 
because they readily adhere to plastic culture dishes and form fibroblast-like 
colonies.(44,46)  Friedenstein et al. initially exploited the ability of these cells to 
adhere to the plastic of the tissue-culture dishes as a means of isolating them from 
the bone marrow.  A standard liquid culture system was developed for isolation of 
the MSCs.  Friedenstein et al. also noted that under these conditions, the MSCs 
grew as foci with fibroblast-like morphology and appeared to be clonal in nature.  By 
using the nomenclature used in colony assay for hematopoietic precursors, these foci 
of cells derived from clonal expansion of single MSC precursors were 
termed—colony-forming-unit fibroblasts (CFU-F).  CFU-F is recognized as the early 
osteoblastic cell precursors.  By counting the number of CFU-Fs, the clonogenic 
precursors, the CFU-F assay is routinely used to quantitate the relative abundance of 
MSCs in bone marrow.(44,46-48)   
Friedenstein et al. later reported that these MSCs, from the bone marrow, possess 
the potential to differentiate along multiple, non-hematopoietic,  mesenchymal cell 
lineages, including osteocytes, chondrocytes, and adipocytes.(44,47,48)  Since the 
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CFU-F’s are a heterogeneous population of stem and progenitor cells, their 
differentiation in vitro can be modified at the colony level.  With the addition of 
ascorbic acid and dexamethasone, the differentiation of the plastic adherent cells can 
be modified in vitro to give rise to cells capable of forming mineralized 
nodules—colony-forming-unit osteoblasts (CFU-OB).(46)   
 
Animal model—inbred mouse strains 
Using inbred strains of mice, various studies have shown that genetic differences 
play a role in bone properties and bone cell biology, such as bone-regenerative 
capacity.  Beamer et al. reported genetic variability in adult bone density among 11 
inbred strains of mice.(49)  Comparison of bone parameters, such as total and 
cortical density, mineral and volume, between the 11 strains revealed that the strain 
C3H/HeJ (C3H) had the highest value for any given bone parameter, and values from 
the C57BL/6J (B6) strain were absolutely and statistically the lowest.  Akhter et al. 
assessed breed-related differences in bone histomorphometry, bone biomechanics 
and serum biochemistry in three mouse strains, C3H/HeJ, C57BL/6J, and DBA/2J, 
shown to differ in bone mineral density.(50)  Similar to other reports, of the strains 
tested, C3H mice had higher bone mineral density, greater bone volume and 
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biomechanical strength.  A variation in distribution of cortical bone in the three 
mouse strains was also noted, and was suggested to represent a difference in 
adaptive response to mechanical loading and a result of strain-specific genetically 
regulated cellular mechanisms.  Genetic variations in bone properties and bone 
metabolism have been extensively investigated, often using the two genetically 
distinct inbred strains of mice, C3H and B6.(51-53)  Compared to B6 mice, C3H 
mice have higher peak bone density(37,52), higher serum alkaline phosphatase (ALP) 
activity(51), higher rate of bone formation(54), lower rate of bone resorption(51,52), 
higher osteoblastic activity(53,55), and lower number of osteoclasts(52).  
Differences in peak bone mass between these two inbred strains have been identified 
as the result of genetic differences, and thus they are commonly chosen as model to 
investigate mechanisms controlling bone density and bone biology.   
The use of CFU-F and CFU-OB assays provides an opportunity for the 
assessment of the effects of in vivo ALN treatment, alone and with fluoride, on early 
and late osteoblastic cell precursors of different inbred strains of mice.   We also 
had the opportunity to investigate the inter-strain responses to ALN treatment (+/- 
fluoride).  Four strains of mice, C57BL/6J (B6), BALB/cJ (BALB-c), C3H/HeJ (C3H), 
and FVB/NJ (FVB) were selected based on differences in genetics, bone biology and 
  10
wound healing characteristics.(39,56,57)  The current study operates under the 
hypotheses that systemic exposure of ALN will affect the bone marrow pool of 
mesenchymal stem cells (MSCs) capable of forming early (CFU-F) or late (CFU-OB) 
osteoprogenitor colonies in a strain-specific manner; and that fluoride will modulate 
ALN’s effects on the MSC pool in the bone marrow when genetic background is a 
factor.
 
 
 
 
CHAPTER 2 
MATERIALS AND METHODS 
Animals 
 Male mice of the inbred strains C57BL/6J (B6), BALB/cJ (BALB-c), C3H/HeJ 
(C3H), and FVB/NJ (FVB) were obtained from the Jackson Laboratory (Bar Harbor, 
ME) at 5 weeks of age.  The mice were acclimated for 1 week in the UNC Dental 
Research Center Bioresearch Facility.  Food and water were provided ad libitum.  A 
laboratory rodent diet LabDiet® 5001 (PMI® Nutrition International) was provided and 
contained 0.95% calcium, 0.67% phosphorous, 4.5 IU/gm vitamin D3, and an 
average [F] of 6.56±0.28 μg/gm.  Mice from each strain were caged in trios and 
housed in the Division of Lab Animal Medicine facility within the Dental Research 
Center, a fully AAALAC accredited unit, at an ambient temperature of 21°C and 
maintained on a 12:12 h light/dark cycle.  All experimental procedures were 
approved by the IACUC at the University of North Carolina at Chapel Hill 
(UNC-IACUC approved protocol #06-118). 
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In vivo ALN and F treatments 
 A total of 64 mice per strain were used for this study.  After 1 week of 
acclimation, 8 mice per strain were randomly assigned to one of 8 treatment groups 
(Group 1 = ALN 3 μg/kg/week, F 0 ppm; Group 2 = ALN 3 μg/kg/week, F 50 ppm; 
Group 3 = ALN 30 μg/kg/week, F 0 ppm; Group 4 = ALN 30 μg/kg/week, F 50 ppm; 
Group 5 = ALN 150 μg/kg/week, F 0 ppm; Group 6 = 150 μg/kg/week, F 50 ppm; 
Group 7 = ALN 0 μg/kg/week, F 0 ppm; and Group 8 = ALN 0 μg/kg/week, F 50 ppm). 
Fluoride ion (0 or 50ppm) was provided as NaF in drinking water.  Alendronate 
(ALN) (alendronate sodium, a gift from Merck Research Laboratories, Rahway, NJ) 
was prepared in 0.9% w/v NaCl and administered subcutaneously (s.c.).  The four 
different levels of ALN treatments were as follows:  
0 ALN (vehicle control): For the control groups, 0.9% NaI was administered s.c. 
weekly (once on Mondays). 
Low dose of ALN: 3 μg/kg/week as a single weekly dose s.c. (once on Mondays).  
This dose has previously been shown to significantly increased the number of CFU-F 
colonies in the bone marrow from young and old animals and better permit 
assessment of bone-forming effects of low dose ALN in osteoporosis.(17)  This 
suggests that bisphosphonates, in vivo, may have a potentially relevant influence on 
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cells of the osteoblastic lineage, distinct from their inhibitory action on osteoclasts. 
Intermediate dose of ALN: 30 μg/kg/week administered 2 times/week at 15μg/kg s.c. 
(Monday and Friday).  This dose was shown to stop bone loss in ovariectomized 
rats.(58) 
High dose of ALN:  150μg/kg/week administered 2 times/week at 75μg/kg s.c. 
(Monday and Friday).  It was anticipated that mice required 5 times the dose as rats.  
This was the equivalent dose for mice which may totally prevent bone loss without 
toxic effect. 
 After the treatment period of 3 weeks, the mice were euthanized.  Bone marrow 
cells were flushed and collected from the tibia and femur from one hind leg of each 
animal. 
 
Colony forming unit-fibroblast (CFU-F) assays   
The bone marrow cells obtained from the mice were plated in triplicate cultures 
(six-well plates) at 2 different densities (5.0 x 105cells/well and 1.0 x 106cells/well) 
using complete media prepared with MesenCultTM Basal Medium and Mesenchymal 
stem cell Stimulatory Supplements (StemCell Technologies; Vancouver, BC, Canada).  
The bone marrow cells were plated according to the protocol provided by the 
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company.  The formation of CFU-F was evaluated after 14 days of culture in a 
humidified 5% CO2/37oC environment.  Cultures were washed with calcium and 
magnesium free Dulbecco’s phosphate buffered saline (PBS) twice and then fixed 
with cold ethanol.  CFU-Fs were stained with Giemsa stain and then colonies 
containing >50 cells counted using light microscopy. 
 
Colony forming unit-osteoblast (CFU-OB) assays  
Bone marrow cells collected from mice were plated in triplicate cultures (six-well 
plates) at 2 different densities (5.0 x 105cells/well and 1.0 x 106cells/well) as 
described above.  The complete media used was prepared from MesenCultTM Basal 
Medium and Mesenchymal stem cell Stimulatory Supplements (StemCell 
Technologies; Vancouver, BC, Canada) with the addition of 50μg/mL of ascorbic acid 
and 10-8M dexamethasone.  After the incubation period of 14 days, the cultures 
were terminated by washing with PBS twice and then fixed with cold ethanol.  
Formation of osteoblast progenitors was detected using an alkaline phosphatase 
assay (86-R, Sigma).  The alkaline phosphatase positive (ALP+) colonies with >50 
cells were counted using light microscopy.  Afterwards, the plates were washed with 
borate buffer (10mM boric acid, adjusted pH to 8.8 with NaOH) and stained with 
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borate buffer containing 1% w/v methylene blue for total colonies.  The colonies with 
>50 cells were counted using light microscopy to obtain a total count of colonies 
present. 
 
Statistics 
Results of the CFU-F and CFU-OB assays were reported as mean ± SD of the 
triplicate cultures.  For each variable, effects across treatment groups were 
compared using one-way ANOVA.  For comparison of treatment groups in pairs, 
Student’s t-test was used.  Adjusted p-values < 0.05 were considered significant. 
 
 
 
 
 
CHAPTER 3 
RESULTS 
Isolation of stromal cells from bone marrow 
 As stated above, mesenchymal stem cells (MSCs) adhere to the plastic of the 
tissue culture plates and thus allow for their isolation from the bone marrow cells 
(BMCs).  MSCs proliferate into colonies and represent a unique cell population 
capable of differentiating along multiple mesenchymal cell lineages.  Microscopic 
examination showed that plastic adherent cell cultures derived from BMCs consisted 
of a heterogeneous collection of morphologically distinctive cell types.(48,59)  An 
example of a typical plastic adherent cell colony, taken from a B6 culture, viewed 
using light microscopy under various magnifications (40X, 100X, 200X and 400X) 
was shown in Figure 4.  Higher magnifications of the colony showed that it contained 
fibroblastoid-shaped cells, some round cells and also stellate cells.  The nature of 
the various cell types observed had not been well characterized or understood.(59,60)  
Although observations from our present study agreed with that from Phinney et al.(59) 
suggesting that the fibroblastoid-shaped cells displayed higher levels of ALP 
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expression, we did not investigate the specific cell types related to ALP expression 
and thus no conclusion can be drawn as to the nature of the different cell types 
present. 
 
Figure 4. Plastic adherent colony stained with Giemsa stain viewed under light 
microscope at magnifications of 40X, 100X, 200X and 400X. 
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CFU-F & CFU-OB assays 
The results from the CFU-F and CFU-OB assays following alendronate (ALN) 
and fluoride (F) treatment are presented in Tables 1 and 2.  As shown, at the density 
of 5x105 BMCs/well, a large number of treatment groups (from B6, FVB and C3H 
strains of mice) had mean CFU-OB, both alkaline phosphatase positive (ALP+) and 
total count, of less than one colony per well.  This means that at this density, so few 
precursors for CFU-OB were present that the colonies failed to thrive, and that the 
comparison of treatment groups using statistical analysis of the data obtained from 
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this plating density would have been misleading. This finding was in agreement with 
that of Phinney et al.(59)  They investigated the frequency of CFU-F of four different 
strains of mice, one of which is B6.  The protocol and size of tissue culture plates 
used in their study were different from our study.  Also, only one plating density was 
used.  However, they reported that at the plating density used in their study, the yield 
of plastic adherent cells is so low from B6 that the cultures failed to thrive in vitro by 
day 15.  Our data shows that, when the plating density was doubled at 1x106 
BMCs/well, for all treatment groups, the mean CFU-F increased about two-folds, 
reflective of the increase in plating density; the mean CFU-OB, on the other hand, 
increased much more than two-fold because the CFU-OB populations were growing 
successfully at the higher plating density, compared to the few colonies present at the 
lower plating density.  At 1x106 BMCs/well, the mean CFU-Fs of all four strains are 
comparable to the corresponding mean CFU-OBs.  The data obtained from this 
higher plating density better reflected the differences in colony forming unit potentials 
of the BMCs from the various strains mice.  Giuliani et al. also used the same plating 
density of 1x106 BMCs/well when they investigated the effect of BPN on formation of 
osteoblast precursors for murine BMCs.(17)  The CFU-F protocol used in their study 
was similar to that of ours, with some differences.  A lower plating density was not 
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used in their study.  Statistical analysis for the study was performed using only data 
obtained from BMCs plated at 1x106 BMCs/well. 
 
Table 1. Mean colony forming unit-fibroblast (CFU-F) following ALN and F treatment 
plated as triplicate cultures at [5x105 BMCs/well] and [1x106 BMCs/well] 
 
Treatment 
Group* 
CFU-F @ [5x105 BMCs/well] CFU-F @ [1x106 BMCs/well] 
Mean SD Mean SD 
B6 -1 2.56 1.74 9.89 4.01 
B6 -2 2.11 1.45 6.67 5.57 
B6 -3 3.11 4.23 9.56 9.58 
B6 -4 3.89 4.78 7.33 6.08 
B6 -5 2.89 2.37 7.44 6.31 
B6 -6 1.33 1.22 6.00 3.57 
B6 -7 4.00 3.57 13.00 6.14 
B6 -8 2.11 2.03 7.89 2.71 
BALB-c -1 17.89 6.85 35.00 14.02 
BALB-c -2 16.89 6.86 34.44 12.74 
BALB-c -3 17.44 5.05 34.78 4.79 
BALB-c -4 17.89 4.88 32.78 6.04 
BALB-c -5 14.56 4.03 29.44 3.75 
BALB-c -6 13.33 3.24 29.44 3.78 
BALB-c -7 14.00 5.24 28.22 7.12 
BALB-c -8 13.67 3.54 29.89 6.17 
C3H -1 10.22 5.42 16.56 5.50 
C3H -2 7.89 3.48 15.78 2.77 
C3H -3 9.67 5.96 17.22 7.36 
C3H -4 8.56 4.61 15.33 5.34 
C3H -5 4.89 2.42 11.22 2.44 
C3H -6 5.56 2.46 12.56 1.51 
C3H -7 11.00 4.12 20.33 5.66 
C3H -8 7.22 3.56 13.11 5.23 
FVB -1 3.78 2.22 11.33 3.84 
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FVB -2 2.67 2.40 11.44 5.20 
FVB -3 6.33 4.66 13.56 8.85 
FVB -4 5.44 3.17 16.11 5.11 
FVB -5 3.56 1.94 10.78 4.06 
FVB -6 2.56 2.19 10.11 6.43 
FVB -7 6.89 2.85 10.56 4.82 
FVB -8 3.44 3.21 9.11 5.73 
*Group 1 = ALN 3 μg/kg/week; F 0 ppm; Group 2 = ALN 3 μg/kg/week; F 50 ppm;  
Group 3 = ALN 30 μg/kg/week; F 0 ppm; Group 4 = ALN 30μg/kg/week; F 50 ppm;  
Group 5 = ALN 150 μg/kg/week; F 0 ppm; Group 6 = ALN 150 μg/kg/week; F 50 ppm;  
Group 7 = ALN 0 μg/kg/week; F 0 ppm; and Group 8 = ALN 0 μg/kg/week; F 50 ppm    
 
 
Table 2. Mean colony forming unit-osteoblast (CFU-OB) following ALN and F 
treatment plated as triplicate cultures at [5x105 BMCs/well] and [1x106 BMCs/well] 
 
Treatment 
Group* 
CFU-OB @ [5x105 BMCs/well] 
ALP +              Total 
CFU-OB @  [1x106 BMCs/well] 
ALP+                Total 
Mean SD Mean SD Mean SD Mean SD 
B6 -1 0.22 0.44 1.00 1.12 2.78 2.39 6.89 3.02 
B6 -2 0.11 0.33 0.78 1.30 1.44 1.24 4.67 2.40 
B6 -3 0.56 1.01 1.00 1.58 4.22 4.87 9.33 8.69 
B6 -4 0.67 1.12 1.22 1.64 2.89 2.93 8.00 5.48 
B6 -5 0.33 0.5 1.00 1.12 3.56 4.25 7.67 6.60 
B6 -6 0.11 0.33 0.44 0.88 1.00 1.12 3.33 3.08 
B6 -7 3.00 4.33 4.33 6.42 3.56 4.00 8.33 4.42 
B6 -8 0.44 0.88 0.56 0.88 3.22 2.73 7.56 5.13 
BALB-c -1 6.89 4.34 10.67 6.20 20.33 9.11 31.89 12.59 
BALB-c -2 5.00 2.78 8.22 4.17 18.78 6.85 31.22 10.50 
BALB-c -3 6.11 3.18 9.44 4.28 18.44 3.81 31.89 3.95 
BALB-c -4 4.00 1.66 6.56 2.30 18.56 2.70 31.00 3.00 
BALB-c -5 4.22 1.48 6.44 2.79 17.89 2.71 28.22 4.18 
BALB-c -6 3.56 3.05 5.33 3.64 17.67 3.32 29.56 2.96 
BALB-c -7 5.11 3.69 7.44 5.17 15.78 5.93 26.00 7.70 
BALB-c -8 4.22 1.48 7.67 3.08 16.78 2.95 26.44 3.47 
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C3H -1 1.00 0.87 3.22 1.09 8.89 5.13 17.11 8.71 
C3H -2 1.11 1.05 3.22 3.77 5.67 2.24 14.44 3.54 
C3H -3 2.00 1.73 5.67 4.61 8.56 6.29 18.11 11.44 
C3H -4 1.11 1.76 3.44 3.84 6.22 5.33 13.89 10.95 
C3H -5 1.22 1.20 3.67 2.35 5.11 1.96 10.33 4.06 
C3H -6 0.22 0.44 1.78 1.56 5.67 2.55 11.56 5.34 
C3H -7 2.22 2.28 6.11 4.43 7.22 3.70 19.56 8.05 
C3H -8 0.89 0.78 3.33 2.55 2.89 1.36 9.00 4.53 
FVB -1 0.44 0.73 0.78 1.20 4.78 3.99 9.11 6.75 
FVB -2 0.78 1.30 1.00 1.80 5.00 4.44 6.78 5.87 
FVB -3 1.78 2.17 2.89 3.14 6.56 5.83 12.44 10.85 
FVB -4 2.33 2.40 2.78 2.86 5.33 3.67 9.33 6.63 
FVB -5 1.11 1.05 2.00 1.58 4.33 2.65 6.89 3.72 
FVB -6 1.78 2.28 2.33 2.78 5.56 4.59 8.33 6.86 
FVB -7 1.00 1.32 2.22 1.79 7.33 5.48 12.22 8.53 
FVB -8 1.00 1.32 2.00 2.55 5.89 6.11 10.33 9.35 
*Group 1 = ALN 3 μg/kg/week; F 0 ppm; Group 2 = ALN 3 μg/kg/week; F 50 ppm;  
Group 3 = ALN 30 μg/kg/week; F 0 ppm; Group 4 = ALN 30μg/kg/week; F 50 ppm;  
Group 5 = ALN 150 μg/kg/week; F 0 ppm; Group 6 = ALN 150 μg/kg/week; F 50 ppm;  
Group 7 = ALN 0 μg/kg/week; F 0 ppm; and Group 8 = ALN 0 μg/kg/week; F 50 ppm 
 
Colony forming unit-fibroblast (CFU-F) 
 The intrinsic differences between strains were observed with the comparisons of 
mean CFU-F from control groups of the four strains tested (Table 3, Figure 5).  
BALB-c mice demonstrated a significantly higher mean CFU-F, of 28.22 ± 7.12, 
compared to B6 (13.00 ± 6.14; p<0.0001), FVB (10.56 ± 4.82; p<0.0001), and C3H 
(20.33 ± 5.66; p=0.0088).  Of the four strains, FVB had the fewest mean CFU-F and 
this difference was significant when compared to C3H (p=0.0016) and BALB-c 
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(p<0.0001), but not B6. 
 
Table 3. Colony forming units (CFUs) fibroblast and osteoblast following ALN and F 
treatment from triplicate cultures at [1x106 BMCs/well] 
 
Treatment 
Group* 
CFU-F# CFU-OB/ALP+ CFU-OB/total 
Mean SD Mean SD Mean SD 
B6-1 9.89 4.01 2.78 2.39 6.89 3.02 
B6-2 6.67 5.57 1.44 1.24 4.67 2.40 
B6-3 9.56 9.58 4.22 4.87 9.33 8.69 
B6-4 7.33 6.08 2.89 2.93 8.00 5.48 
B6-5 7.44 6.31 3.56 4.25 7.67 6.60 
B6-6 6.00 3.57 1.00 1.12 3.33 3.08 
B6-7 13.00 6.14 3.56 4.00 8.33 4.42 
B6-8 7.89 2.71 3.22 2.73 7.56 5.13 
BALB-c -1 35.00 14.02 20.33 9.11 31.89 12.59 
BALB-c -2 34.44 12.74 18.78 6.85 31.22 10.50 
BALB-c -3 34.78 4.79 18.44 3.81 31.89 3.95 
BALB-c -4 32.78 6.04 18.56 2.70 31.00 3.00 
BALB-c -5 29.44 3.75 17.89 2.71 28.22 4.18 
BALB-c -6 29.44 3.78 17.67 3.32 29.56 2.96 
BALB-c -7 28.22 7.12 15.78 5.93 26.00 7.70 
BALB-c -8 29.89 6.17 16.78 2.95 26.44 3.47 
C3H-1 16.56 5.50 8.89 5.13 17.11 8.71 
C3H-2 15.78 2.77 5.67 2.24 14.44 3.54 
C3H-3 17.22 7.36 8.56 6.29 18.11 11.44 
C3H-4 15.33 5.34 6.22 5.33 13.89 10.95 
C3H-5 11.22 2.44 5.11 1.96 10.33 4.06 
C3H-6 12.56 1.51 5.67 2.55 11.56 5.34 
C3H-7 20.33 5.66 7.22 3.70 19.56 8.05 
C3H-8 13.11 5.23 2.89 1.36 9.00 4.53 
FVB-1 11.33 3.84 4.78 3.99 9.11 6.75 
FVB -2 11.44 5.20 5.00 4.44 6.78 5.87 
FVB -3 13.56 8.85 6.56 5.83 12.44 10.85 
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FVB -4 16.11 5.11 5.33 3.67 9.33 6.63 
FVB -5 10.78 4.06 4.33 2.65 6.89 3.72 
FVB -6 10.11 6.43 5.56 4.59 8.33 6.86 
FVB -7 10.56 4.82 7.33 5.48 12.22 8.53 
FVB -8 9.11 5.73 5.89 6.11 10.33 9.35 
*Group 1 = ALN 3 μg/kg/week; F 0 ppm; Group 2 = ALN 3 μg/kg/week; F 50 ppm;  
Group 3 = ALN 30 μg/kg/week; F 0 ppm; Group 4 = ALN 30μg/kg/week; F 50 ppm;  
Group 5 = ALN 150 μg/kg/week; F 0 ppm; Group 6 = ALN 150 μg/kg/week; F 50 ppm;  
Group 7= ALN 0μg/kg/week; F 0 ppm; and Group 8 = ALN 0 μg/kg/week; F 50 ppm                
#mean CFU colonies / 1x106 BMCs from triplicate cultures 
 
 
Figure 5. Comparison of mean CFU-F of control groups from 4 mice strains (F=0ppm) 
plated at [1x106 BMCs/well] 
 
 
 
 The different mice strains also displayed intrinsic differences in the rate of 
expansion of the plastic adherent colonies.  Figure 6 displayed the tissue culture 
plates from the CFU-F assays of the control groups of the four mice strains.  One 
can appreciate that the plates from the different strains did not only differ in the 
number of colonies present, but also in the size of the colonies.  B6 strain displayed 
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the least number of colonies at the lower plating density of [5x105BMCs/well], with no 
colonies at all in some of the wells.  The colonies present for B6, however, are 
slightly larger in size than the colonies present for C3H and BALB-c strains.  Both 
C3H and BALB-c strains displayed higher number colonies that were smaller in size, 
with BALB-c strain showing the highest number of colonies present than all other 
three strains.  FVB strain displayed fewest colonies, but the sizes of the colonies 
present were larger than those of the other strains. 
 
Figure 6. CFU-F plates of control groups of the 4 mice strains at [1]=[5x105BMCs/well] 
and [2]= [1x106 BMCs/well] 
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Comparisons were made for the mean CFU-F between groups of mice, within 
each strain, treated with different levels of ALN, with the absence and presence of F 
in drinking water (F=0ppm and F=50ppm).  As seen in figures 7-10, for the B6, 
BALB-c and FVB strains, no significant differences were noted between the mean 
CFU-F of groups, within the same strain, receiving the same fluoride dose but varying 
ALN doses.  However, in the C3H strain, in the absence of F, the group that received 
a high dose of ALN (150μg/kg/week) displayed significantly fewer number of CFU-F 
(11.22 ± 2.44) compared to the control (20.33 ± 5.66; p=0.0014).  Nevertheless, for 
all four strains tested, no dose response to ALN was observed.  
 
Figure 7.  Comparison of mean CFU-F from B6 mice treated with different levels of 
ALN plated at [1x106/well] 
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Figure 8.  Comparison of mean CFU-F from BALB-c mice treated with different 
levels of ALN plated at [1x106/well] 
 
 
 
Figure 9.  Comparison of mean CFU-F from C3H mice treated with different levels of 
ALN plated at [1x106/well]  
 
 
Figure 10.  Comparison of mean CFU-F from FVB mice treated with different levels 
of ALN plated at [1x106/well]  
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Comparisons were made between treatment groups, within each strain of mice, 
treated with the same dose of ALN, but received different dose of F in drinking water 
(0ppm or 50ppm). (Figure 11-14)  In the absence of ALN treatment (ALN=0), the 
presence of 50ppm of fluoride in drinking water did not significantly alter the 
frequency of CFU-F’s for BALB-c and FVB mice; Significantly fewer mean CFU-Fs 
were observed in groups of B6 mice treated with fluoride (7.89 ± 2.71) compared 
control (13.00 ± 6.14; p=0.036) and C3H mice treated with fluoride (13.11 ± 5.23) 
compared to control (20.33 ± 5.66; p=0.013).  When comparisons were made 
between groups receiving the same levels of ALN, no significant difference was noted 
between the mean CFU-F of groups treated with and without fluoride.  This was true 
for all four strains of mice.  In the context of both ALN and fluoride treatment, within 
all four strains, there was no significant difference between the mean CFU-F of 
groups receiving the same ALN dose but different fluoride dose. 
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Figure 11.  Comparison of mean CFU-F from B6 mice treated with & without fluoride 
plated at [1x106/well] 
 
 
 
Figure 12.  Comparison of mean CFU-F from BALB-c mice treated with & without 
fluoride plated at [1x106/well] 
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Figure 13.  Comparison of mean CFU-F from C3H mice treated with & without 
fluoride plated at [1x106/well] 
 
 
 
Figure 14.  Comparison of mean CFU-F from FVB mice treated with & without 
fluoride plated at [1x106/well] 
 
  32
Colony forming unit-osteoblast (CFU-OB) 
 The normal differences noted between the mean CFU-F of different strains were 
also observed with the CFU-OB assay.  A comparison of the number of alkaline 
phosphatase positive CFU-OB (CFU-OB/ALP+) from the control groups of the four 
strains (Figure 15) revealed that BABL-c (15.78 ± 5.93) displayed a significantly 
higher number of CFU-OB/ALP+ than B6 (3.56 ± 4.00; p<0.0001), C3H (7.22 ± 3.70; 
p=0.0008) and FVB (7.33 ± 5.48; p=0.0009).  When the total numbers of CFU-OB 
(CFU-OB/total) were counted, a greater difference between the strains was noted.  
As displayed in Figure 16, BALB-c (26.00 ± 7.70) had significantly higher number of 
CFU-OB/total compared to B6 (8.33 ± 4.42; p<0.0001) and FVB (12.22 ± 8.53; 
0.0004); C3H (19.56 ± 8.05) also displayed significantly higher number of CFU-OB 
compared to B6 (p=0.0028) and FVB (p=0.0422).  Intrinsic differences were again 
observed in the ratios of the total CFU-OB that were ALP+ in the control groups of the 
individual strain.  As shown in Figure 17, both BALB-c and FVB showed higher 
ALP+/total CFU-OB ratios, at 0.60 ± 0.10 and 0.50 ± 0.20 respectively, than B6 (0.32 
± 0.31; BALB-c, p=0.004; FVB, p=0.006) and C3H (0.36 ± 0.07; BALB-c, p=0.011; 
FVB, p=0.017). 
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Figure 15. Comparison of mean CFU-OB/ALP+ of control groups from 4 mice strains 
(F=0ppm) plated at [1x106/well] 
 
 
 
Figure 16. Comparison of mean CFU-OB/total of control groups from 4 mice strains 
(F=0ppm) plated at [1x106/well] 
 
 
 
Figure 17. Comparison of mean CFU-OB (ALP+/total) ratio of control groups from 4 
mice strains (F=0ppm) plated at [1x106/well] 
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An analysis of the results from groups within the B6 strain (Figures 18-20) 
demonstrated that when F level remained 0ppm, the increase in ALN dose did not 
result in significant changes in the frequency of CFU-OB/ALP+, CFU-OB/total, or the 
CFU-OB (ALP+/total) ratio.  However, when the mice received 50ppm of F in the 
drinking water, there were significant differences in the number of CFU-OB/ALP+ 
between the group receiving no ALN (3.22 ± 2.73) and the group receiving 
150μg/kg/week of ALN (1.00 ± 1.12; p=0.0373); significant differences were also 
noted in the mean CFU-OB/total between the group treated with no ALN (7.56 ± 5.13) 
and the group treated with 150μg/kg/week of ALN (3.33 ± 3.08; p=0.0420), and 
between the group treated with 30μg/kg/week of ALN (8.00 ± 5.48) and the group 
treated with 150μg/kg/week of ALN (p=0.0256).  No significant difference was 
observed in the changes of mean CFU-OB (ALP+/total) ratios in response to 
increasing levels of ALN for the groups treated with 50ppm of F.   
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Figure 18. Comparison of mean CFU-OB/ALP+ from B6 mice treated with different 
levels of ALN plated at [1x106/well] 
 
 
 
Figure 19. Comparison of mean CFU-OB/total from B6 mice treated with different 
levels of ALN plated at [1x106/well] 
 
 
 
Figure 20. Comparison of mean CFU-OB (ALP+/Total) ratio from B6 mice treated with 
different levels of ALN plated at [1x106/well] 
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Comparisons were also made between groups of B6 mice receiving 0 ppm F and 
50ppm of F in drinking water, but treated with the same ALN doses.  When the dose 
of ALN remained constant, no significant difference was noted, between groups 
treated with and without fluoride, in the mean CFU-OB/ALP+ (Figure 21), the mean 
CFU-OB/total (Figure 22), and the mean CFU-OB (ALP+/total) ratio (Figure 23).   
 
Figure 21. Comparison of mean CFU-OB/ALP+ from B6 mice treated with & without 
fluoride plated at [1x106/well] 
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Figure 22. Comparison of mean CFU-OB/total from B6 mice treated with & without 
fluoride plated at [1x106/well] 
 
 
 
Figure 23. Comparison of mean CFU-OB (ALP+/Total) ratio from B6 mice treated with 
& without fluoride plated at [1x106/well] 
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Analysis of the data from BALB-c mice revealed that as the level of F remained 
constant, either at 0ppm or 50ppm, the increase in ALN dose did not have a 
significant effect on the frequencies of mean CFU-OB/ALP+ (Figure 24), mean 
CFU-OB/total (Figure 25), and the mean CFU-OB (ALP+/total) ratio (Figure 26).  
There was also no significant difference in the mean CFU-OB/ALP+ (Figure 27), the 
mean CFU-OB/total (Figure 28), and the mean CFU-OB (ALP+/total) ratio (Figure 29) 
between groups receiving the same ALN dose, but different doses of F (0ppm or 
50ppm).   
 
Figure 24. Comparison of mean CFU-OB/ALP+ from BALB-c mice treated with 
different levels of ALN plated at [1x106/well] 
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Figure 25. Comparison of mean CFU-OB/total from BALB-c mice treated with 
different levels of ALN plated at [1x106/well] 
 
 
 
Figure 26. Comparison of mean CFU-OB (ALP+/total) ratio from BALB-c mice treated 
with different levels of ALN plated at [1x106/well] 
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Figure 27. Comparison of mean CFU-OB/ALP+ from BALB-c mice treated with & 
without fluoride plated at [1x106/well] 
 
 
 
Figure 28. Comparison of mean CFU-OB/total from BALB-c mice treated with & 
without fluoride plated at [1x106/well] 
 
 
  41
Figure 29. Comparison of mean CFU-OB (ALP+/total) ratio from BALB-c mice treated 
with & without fluoride plated at [1x106/well] 
 
 
The results from C3H mice showed some interesting relationships between 
treatment groups.  When level of F remained at 0ppm, no significant difference was 
observed in the mean CFU-OB/ALP+ between treatment groups receiving different 
doses of ALN (Figure 30); However, a significant decrease in the mean CFU-OB/total 
was noted in the group receiving 150μg/kg/week of ALN (10.33 ± 4.06) compared to 
the control (ALN=0) (19.56 ± 8.05; p=0.028) (Figure 31); There were also significant 
increases in the mean CFU-OB (ALP+/total) ratio in response to increased levels of 
ALN reflected by the comparisons made between the control group (ALN=0) (0.36 ± 
0.07) and the groups receiving 3μg/kg/week of ALN (0.49 ± 0.14; p=0.0116), and 
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150μg/kg/week of ALN (0.51 ± 0.11; p=0.004) (Figure 32).  On the other hand, when 
level of F remained constant at 50ppm, a significant increase in the mean 
CFU-OB/ALP+ was noted in the group treated with 30μg/kg/week of ALN (6.22 ± 5.33) 
compared to the control (2.89 ± 1.36; p=0.0361) (Figure 30); However, the changes in 
the mean CFU-OB/total (Figure 31) and the mean CFU-OB (ALP+/total) ratio (Figure 
32), in response to increasing levels of ALN, were not significant.   
 
Figure 30. Comparison of mean CFU-OB/ALP+ from C3H mice treated with different 
levels of ALN plated at [1x106/well] 
 
 
 
Figure 31. Comparison of mean CFU-OB/total from C3H mice treated with different 
levels of ALN plated at [1x106/well] 
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Figure 32. Comparison of mean CFU-OB (ALP+/Total) ratio from C3H mice treated 
with different levels of ALN plated at [1x106/well] 
 
 
Comparisons were then made between C3H groups receiving the same levels of 
ALN, but different levels of F (0ppm or 50ppm).  At ALN dose of 0, significantly fewer 
mean numbers CFU-OB/ALP+ and CFU-OB/total were present in the group treated 
with 50ppm F (ALP+ 2.89 ± 1.36; total 9.00 ± 2.18) compared to the group not treated 
with F (ALP+ 7.22 ± 0.93; p=0.005; total 19.56 ± 2.18; p=0.003).  At higher doses of 
ALN, no difference was observed in the mean number of CFU-OB/ALP+ or the mean 
CFU-OB/total between groups treated with and without F. (Figure 33, 34) The 
differences in mean CFU-OB (ALP+/total) ratio between groups treated with and 
without F, at the various levels of ALN, were not significant (Figure 35).   
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Figure 33. Comparison of mean CFU-OB/ALP+ from C3H mice treated with & without 
fluoride plated at [1x106/well] 
 
 
 
Figure 34. Comparison of mean CFU-OB/total from C3H mice treated with & without 
fluoride plated at [1x106/well] 
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Figure 35. Comparison of mean CFU-OB (ALP+/Total) ratio from C3H mice treated 
with & without fluoride plated at [1x106/well] 
 
 
The same analyses were performed for results from the FVB strain.  As 
displayed in Figures 36-38, as the level of F remained constant, no significant change 
in the mean frequency of CFU-OB/ALP+, CFU-OB/total and CFU-OB (ALP+/total) 
ratio was noted in response to increasing doses of ALN.  When comparisons were 
made between groups treated with the same levels of ALN, but different levels of 
fluoride (0ppm or 50ppm), there were no significant differences in the mean 
CFU-OB/ALP+ (Figure 39), mean CFU-OB/total (Figure 40) and mean CFU-OB 
(ALP+/total) ratio (Figure 41).   
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Figure 36. Comparison of mean CFU-OB/ALP+ from FVB mice treated with different 
levels of ALN plated at [1x106/well] 
 
 
 
Figure 37. Comparison of mean CFU-OB/total from FVB mice treated with different 
levels of ALN plated at [1x106/well] 
 
 
 
Figure 38. Comparison of mean CFU-OB (ALP+/Total) ratio from FVB mice treated 
with different levels of ALN plated at [1x106/well] 
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Figure 39. Comparison of mean CFU-OB/ALP+ from FVB mice treated with & without 
fluoride plated at [1x106/well] 
 
 
 
Figure 40. Comparison of mean CFU-OB/total from FVB mice treated with & without 
fluoride plated at [1x106/well] 
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Figure 41. Comparison of mean CFU-OB (ALP+/Total) ratio from FVB mice treated 
with & without fluoride plated at [1x106/well] 
 
 
Summary of effects of F and ALN 
 As shown above, the intrinsic strain dependent differences in CFU-F, 
CFU-OB/ALP+ and CFU-OB/total were observed at baseline.  In summary, fluoride 
alone did not significantly alter the frequencies of CFU-F, CFU-OB/ALP+, or 
CFU-OB/total for BALB-c and FVB mice.  Significant decreases in mean CFU-F 
were found in B6 (p=0.036) and C3H mice (p=0.013) treated with 50ppm fluoride in 
drinking water.  Only the C3H strain demonstrated significant reductions in 
CFU-OB/ALP+ (p=0.005) and CFU-OB/total (p=0.003) with fluoride treatment. 
 Systemic alendronate had no significant effect on the frequencies of CFU-F, 
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CFU-OB/ALP+, or CFU-OB/total for the BALB-c, B6, and FVB strains.  ALN 
treatment alone significantly reduced the frequencies of CFU-F and CFU-OB/total in 
C3H mice in a dose dependent manner, which is greatest between the control and 
the highest dose (150μg/kg/week) (CFU-F p=0.0014; CFU-OB/total p=0.028).  In the 
C3H strain, ALN alone had no significant effect on the frequency of CFU-OB/ALP+.
 
 
 
 
CHAPTER 4 
DISCUSSION 
In our review of the literature, we found that the majority of studies have focused 
upon bisphosphonates’ actions on osteoclasts and osteoblasts.  We chose to 
investigate potential effects of the nitrogen-containing bisphosphonate, alendronate, 
in the context of another bone seeking agent, fluoride, on the bone marrow 
mesenchymal stem cell (MSC) pool.  This study investigated the inter-strain 
responses to ALN treatment (+/- fluoride).  Four strains of mice, C57BL/6J (B6), 
BALB/cByJ (BALB-c), C3H/HeJ (C3H), and FVB/NJ (FVB) were selected based on 
differences in genetics, bone biology and wound healing 
characteristics(39,40,43,56,57,61).  This study tested the hypothesis that systemic 
ALN and F would interact and affect the bone marrow pool of MSCs capable of 
forming early (CFU-F) or late (CFU-OB) osteoprogenitor colonies in a strain-specific 
manner. 
As shown above, colonies formed from murine BMCs under CFU culture 
condition consisted of a variety of morphologically distinct cells.  Some cells were 
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fibroblastoid-shaped, some were round, and some were stellate shaped.  Although 
observations from our present study agreed with that of Phinney et al.(59) suggesting 
that the fibroblastoid-shaped cells displayed higher levels of ALP expression, we did 
not investigate the specific cell types related to ALP expression and thus no 
conclusion can be drawn as to the nature of the different cell types present.   
The intrinsic differences between the isolated bone marrow cells from different 
strains of inbred mice have been investigated extensively.  As reported by Phinney 
et al.(59), MSCs from inbred strains of mice vary greatly in yield, growth and 
differentiation in CFU assays.  As a result, the optimal plating densities vary 
between strains.  Phinney et al. provided direct comparison of frequency of CFU-Fs 
in commonly used inbred strains of mice.  They estimated the frequency of MSCs 
per 106 bone marrow cells as 0.3±0.02 for B6 mice, and 3±0.22 for BALB-c mice.  
The differences in frequencies of CFU-F from the various strains of mice supported 
the findings in our study.  However, the frequencies reported did not match our data 
exactly.  This difference in reported frequencies may have resulted from a difference 
in culture conditions.  We chose to not include the data obtained from BMCs plated 
at 5x105 cells/well in the analyses, as the yield of CFUs was less than 1 for many of 
the groups and may have resulted in misleading conclusions.  We noted that plating 
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density of 5x105 BMCs/well may have been ideal for some strains of mice, but not for 
others which may have required higher plating density to acquire identifiable colonies.  
This finding was supported by those of Peister et al.(60). 
Peister et al. (60)demonstrated that MSCs from different strains of inbred mice 
vary in their media requirements and plating density for optimal growth.  In a 
controlled environment, the MSCs from various strains of mice vary in their rates and 
potential of proliferation.  Their study showed that both BALB-c and B6 MSCs 
expanded more rapidly than FVB.  However, the rate and proliferative potential in 
their study were measured by comparison of cell numbers.  One must note that the 
size of each CFU-F/CFU-OB, thus, the total cell number, vary greatly between strains.  
We did observe significantly higher CFU-F and CFU-OB counts for BALB-c strain 
compared to others.  B6 strain exhibited low counts of CFU-F and CFU-OB.  Our 
findings contradicted that of Peister’s.  However, it was noted during our study that 
B6 MSCs, when successfully adhere to plastic tissue culture plates, form few, but, 
large colonies when plated for CFU-F and CFU-OB assays.  This may account for 
the discrepancy in number of colonies and cell numbers.  Interestingly, Phinney et al. 
also looked at the growth kinetics of plastic adherent cell cultures of the various 
strains of mice.(59)  They also observed high proliferation rate of BALB-c BMCs, 
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about 1.5 – to 4-fold greater than that calculated for FVB BMCs.  Similar to our 
findings, they noted that the growth rate of plastic adherent cultures from B6 BMCs 
were so low that the cultures failed to thrive in vitro.  Interestingly, in our study, even 
though FVB strain had the fewest mean number of CFU-F, its colonies were also 
larger in size than those of the B6 strain.  This was in agreement with the findings 
from the Phinney et al. study showing that B6 plastic adherent cells had the slowest 
growth rate.  A possible explanation for the difference observed between the 
findings from the various studies is that Phinney et al., like our present study, 
observed the differentiation of BMCs plated right after extraction from the bone 
marrow, while Peister et al. studied the rate of proliferation of passage 7 cells.  
Plastic adherent cells from various strains of mice differ in composition of 
morphologically distinct cells and differentiation potential.  It was noted that at 
passage 7, cells from all strains of mice had similar morphologies.  The difference in 
composition of whole marrow cells and passage 7 cells likely contributed to the 
difference in the expansion potential observed for the B6 mice.  Neither groups 
included C3H strain in their studies.  Nevertheless, from our observation of the 
number and size of colonies present, we suspect that the growth rate of the C3H 
plastic adherent cells may be close to that of the BABL-c cells.  However, we could 
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only speculate the growth rates of the cells since no quantitative measures were 
taken in our study to calculate the total number of cells over time. 
The mismatch between the osteoblastic potential of the various strains, 
measured by ALP+/total CFU-OB, the number of osteoprogenitor precursors present 
in the bone marrow, measured by mean CFU-F and CFU-OB, and the reported bone 
mineral density suggest that there are many factors involved in bone metabolism in 
determining the amount of bone present, the mineral content of the bone, and the 
turnover rate of the bone.  It has been shown that the cortical densities and mineral 
contents in C3H femurs were significantly higher than in B6 and BALB-c femurs.(49)  
Data from the Mouse Phenome Database showed that the whole body bone mineral 
density (BMD) (without head) for 8 week old male mice of the four mice strains used 
in our study, arranged from the greatest to the least, were as follows: C3H > FVB > 
BALB-c > B6(62).  The difference in BMD between C3H and B6 has been well 
documented and investigated.  C3H mice, compared to B6 mice, have higher BMD, 
higher serum ALP level, higher bone healing potential and higher number of 
osteoblast precursors in terms of ALP+ colony-forming units in bone marrow cells 
cultures(51,53).  We found that C3H mice, compared to B6 mice, did have 
significantly higher number of CFU-F, ALP+ CFU-OB and total number of CFU-OB.  
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Interestingly, when we compared the ratios of ALP+/total CFU-OB between the two 
strains, no significant difference was found.  It is likely that MSCs from both C3H and 
B6 strains have similar potential in differentiation into osteoblasts despite the 
significantly higher number of early osteoprogenitors found in the C3H strain.  A 
study by Amblard et al. showed that BMD did not depend only on the factors listed 
above, but also on the bone cellular activities.(63)  Bone formation activity, and 
histomorphometric indices of bone formation in the femoral metaphysis and cortical 
tibia were shown to be lower in C3H than B6 mice.  The lower bone cellular activities, 
together with high number of osteoprogenitors, all contributed to the higher bone 
mineral density in C3H mice.   
We also found that MSCs from BALB-c and FVB display similar, and significantly 
higher osteoblast differentiation potential than that of C3H and B6 strains, as shown 
by their ratios of ALP+/total CFU-OB.  This finding is again interesting since BALB-c 
mice, as mentioned earlier, displayed significantly higher counts of CFU-F and 
CFU-OB compared to all three other strains, and FVB mice consistently displayed 
significantly lower counts of CFU-F and CFU-OB compared to that of BALB-c and 
C3H.  One must also note that the whole body BMD of BALB-c is low compared to 
both C3H and FVB mice, despite the higher CFU-F, CFU-OB/ALP+ and CFU-OB/total 
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in BALB-c than the other three strains of mice.  This again suggested that BMD did 
not depend only on the number of osteoprogenitors and their osteoblastic 
differentiation potential.  Similar to the example shown above for C3H and B6 mice, 
other factors such as rate of bone cellular metabolism, rate of bone resorption, 
osteoclastic potentials, etc. may have contributed to the low BMD in BALB-c mice.  
Unfortunately, at this point in time, we can only speculate on the reason for the low 
BMD in BALB-c mice.  The BALB-c mice, unlike C3H or B6, are not typically used 
for bone studies, and thus no data exists, to date, involving other aspects of bone 
metabolism.   
While the four strains differed in baseline frequencies of CFU-F, CFU-OB/ALP+, 
and CFU-OB/total, their responses to alendronate or fluoride were limited.  Our data 
showed no significant change in frequency of CFU-F in response to increasing doses 
of ALN, without the influence of fluoride, in B6, BALB-c and FVB strains.  This 
finding is different from that of the work of Giuliani et al.(17) and Still et al.(16).  Both 
groups of authors reported an increase in colony formation as a result of ALN 
treatment at a low concentration.  However, in both those studies, rats were used as 
the animal model, and ALN was administered in vitro, as part of the medium, for the 
plated MSCs.  In our study, the ALN was administered to the mice in vivo, and then, 
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the MSCs were collected and then plated for CFU-F assay.  This difference in 
method of ALN treatment, together with the species difference, may have resulted in 
the contrasting findings.  Although Still et al. suggested through their experience that 
agents that can stimulate colony formation in CFU-F assay may also be anabolic in 
vivo, this was not observed in our study.  It is also possible that murine CFU-F 
assays produce few colonies at the density and size of tissue culture plate used, 
unlike the hundreds of colonies reported in rat CFU-F studies, and it is difficult for us 
to detect mild effects of the treatments.  Both Giuliani et al. and Still et al. have also 
noted that ALN inhibited colony formation when administered at a high dose.  We 
did not see a significant decrease in number of CFU-F in response to high ALN dose 
in B6, BALB-c or FVB strains of mice.  However, in the C3H strain, although no 
significant change in frequency of CFU-F was observed with low and intermediate 
doses of ALN, high dose of ALN at 150μg/kg/week did result in a significant decrease 
in the number of CFU-F compared to the control.  However, since C3H is the only 
strain of mice with this finding, we are not able to conclude that high dose ALN 
inhibits colony formation of CFU-F in mice.   
Giuliani et al. did include in their study an experiment involving in vivo ALN 
treatment on female Swiss/Weber mice at three different levels ALN treatment.  
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They noted that in vivo ALN treatment, like in vitro treatment, resulted in increase of 
CFU-F formation at low ALN dose, and inhibited CFU-F formation at high ALN dose.  
However, their low and intermediate doses were 0.3μg/kg/week and 3μg/kg/week 
respectively, which were much lower than our doses at 3μg/kg/week and 
30μg/kg/week.  Their high dose of ALN, was 30μg/kg/week, which is the 
intermediate dose used in our study.  This variation in dose and in strains of mice 
used between our study and theirs may have contributed to the difference in results. 
The effect of ALN treatment on CFU-OB was also investigated by Giuliani et 
al.(17)  They noticed that ALN had a biphasic effect on formation of CFU-OB, 
defined by this group as colonies with formation of bone-like nodules.  They believed 
that ALN had a stimulatory effect at low doses and inhibitory effect at high doses.  
The range of the “effective dose” would depend on the bisphosphonate used and the 
species.  The results from our CFU-OB assay did not agree with the observations 
made by Giuliani et al.  Our results from B6, BALB-c and FVB mice failed to show 
significant changes in frequency of ALP+ CFU-OB, total number of CFU-OB, and 
ratio of ALP+/total CFU-OB in response to ALN treatments.  However, the results 
from C3H mice showed significant decrease in number of total CFU-OB in response 
to high dose ALN (150μg/kg/week), yet, the ratio of ALP+/total colonies significantly 
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increased in CFU-OB from groups treated with ALN, compared to control.  This 
suggests that ALN, despite having an inhibitory effect on the number of 
osteoprogenitors available in the bone marrow of C3H mice, it does have stimulatory 
effect on osteoblast differentiation in the available osteoprogenitors.   One must 
note again the differences in our protocol for CFU-OB compared to that of the Giuliani 
group, which may have contributed to the differences in our results.  In their study 
ALN was administered in vitro, and CFU-OB formation was determined by counting 
mineralized nodules positive for Alizarin Red S staining after 21 days of incubation 
using the same growth medium as their CFU-F assay.  In our study, the ALN was 
given to the animal and CFU-OB was determined after 14 days of incubation, using 
growth medium containing dexamethasone and ascorbic acid to promote the 
differentiation of osteoblast precursors, and staining for both ALP+ colonies and total 
colonies. 
Fluoride, known for its anabolic actions on bone, has been suggested by many to 
have anabolic effects on osteoblasts through undetermined mechanism.(33,37,38)  
Fluoride dose-dependent increases in serum ALP activity, in B6 mice, were observed 
by Yan et al.(43).  It was suggested that genetic background may have played a role 
in fluoride’s effects on bone biology.  Fluoride treatment of 50ppm in the drinking 
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water would raise the serum F concentration to a physiologically relevant level of 
approximately 6-10µM/L(43,64).  Our results failed to show fluoride’s anabolic effect 
on the osteoprogenitors in the bone marrow.  In fact, without the influence of ALN 
treatment, no significant change was observed in the number of CFU-F between 
groups treated with and without fluoride for BALB-c and FVB mice.  There was also 
no difference in number of CFU-OB/ALP+, CFU-OB/total and ratio of ALP+/total 
CFU-OB in B6, BALB-c and FVB mice treated with and without fluoride.  However, 
50ppm of fluoride had the most pronounced effect on the C3H strain by reducing the 
frequencies of CFU-F, CFU-OB/ALP+, and CFU-OB/total; despite the lack of change 
in the ratio of ALP+/total CFU-OB compared to the control.  B6 was the only other 
strain that responded to F with a significant reduction in CFU-F.  This variation in 
responses from the different strains of mice suggests that genetic background 
influences fluoride’s effect on osteoblast differentiation.  Our result also suggest that 
fluoride’s anabolic effect on osteoblast does not involve increasing the number of 
osteoprogenitor cells in the bone marrow, nor does fluoride, under our experimental 
conditions, promote osteoblast differentiation.   
As noted above, only few strains having significant difference between treatment 
and control group when treated with only one reagent, bisphosphonate or fluoride 
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alone.  Since both bisphosphonate and fluoride act on the same target site in the 
body, we were interested in seeing whether or not there is a combined effect on the 
osteoblast precursors.    The results from CFU-F assays showed that when [F] 
remained constant at 50ppm, no significant change was observed in the colony 
number between groups receiving different levels of ALN.  Similarly, comparisons 
between groups receiving the same ALN dose, except ALN=0, treated with and 
without fluoride, no significant difference in CFU-F was noted.  Similar results were 
observed with the CFU-OB assays.  No significant difference in ALP+ CFU-OB, total 
number of CFU-OB, or ratio of ALP+/total CFU-OB was observed between groups 
receiving the same ALN dose, not including the groups receiving no ALN, but treated 
with and without fluoride; the same goes for groups treated with 50ppm of fluoride, 
but receiving different doses of ALN.  The only exceptions being B6 mice, which 
showed a significant decrease in number of ALP+ CFU-OB and total CFU-OB when 
treated with a combination of 50ppm of fluoride and 150μg/kg/week of ALN.  
However, for this group of mice, the ratio of ALP+/total CFU-OB was not significantly 
different from the control.  Another exception is the C3H mice, which exhibited 
significantly higher number of ALP+ CFU-OB when treated with 50ppm of fluoride 
and 30μg/kg/week of ALN.  Nevertheless, this combination of treatments did not 
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change the number of total CFU-OB or the ratio of ALP+/total CFU-OB significantly.  
Therefore, in general, no significant difference in CFU-F, ALP+ CFU-OB, total number 
of CFU-OB, or ratio of ALP+/total CFU-OB was noted between treatment groups and 
control when a combination of the two reagents are administered. 
In summary, intrinsic differences between the strains were observed.  When 
ALN or fluoride was administered alone, significant changes in colony counts CFU-F 
or CFU-OB were observed only in few of the treatment groups.  This suggests that 
these reagents have strain-specific effects in mice.  No dose-dependent effect of 
systemic ALN was observed on the murine bone marrow-derived CFU-F and 
CFU-OB.  Given the relatively small number of strains investigated, it would appear 
that the systemic ALN has minimal effects on bone marrow MSC pool and no effect 
on the frequency of osteoblast precursors potential.  Furthermore, fluoride does not 
appear to modulate the effect of ALN on the MSC pool when genetic background is a 
factor. 
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